| Trial name or title |
Rosiglitazone in subjects with type 2 diabetes mellitus who are inadequately controlled on insulin |
| Methods |
A multicenter, randomised, double‐blind, parallel‐group, placebo‐controlled clinical evaluation of insulin plus rosiglitazone (2 mg and 4 mg) compared to insulin plus placebo for 24 weeks |
| Participants |
Participants with type 2 diabetes mellitus who are inadequately controlled on insulin |
| Interventions |
Rosiglitazone + insulin vs insulin + placebo |
| Outcomes |
HbA1c, fasting plasma glucose, lipids |
| Starting date |
22 May 2006 |
| Contact information |
|
| Notes |
GlaxoSmithKline |
